|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Mar 27
|
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
|
|
Mar 26
|
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
|
|
Mar 26
|
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
|
Mar 25
|
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
|
|
Mar 19
|
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
|
|
Mar 19
|
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
|
|
Mar 14
|
Japan’s Stock Market Is Back, and It Isn’t Too Late to Buy
|
|
Mar 13
|
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
|
|
Mar 11
|
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Mar 11
|
TAK or STVN: Which Is the Better Value Stock Right Now?
|
|
Mar 11
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
|
Mar 5
|
Alexandria (ARE) Announces Lease Extension at Kendall Square
|
|
Feb 27
|
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
|
|
Feb 27
|
Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
|
|
Feb 26
|
Championing Rare Voices on Rare Disease Day
|
|
Feb 24
|
11 Best Japanese Stocks To Buy In 2024
|
|
Jan 16
|
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
|
Dec 22
|
One Ultra-Cheap High-Yield Dividend Stock to Buy
|
|
Dec 21
|
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
|